A drug candidate, based on pioneering UCL and Moorfields Eye Hospital research and currently under development by SIFI S.p.A., has been found to be highly effective in treating a rare sight-threatening eye infection in a new international clinical trial.
Bolt Biotherapeutics revamps as it drops lead cancer asset, changes CEO and trims headcount
Bolt Biotherapeutics is reshuffling to cut costs and extend its cash runway to the second half of 2026. The California biotech said Tuesday afternoon that